Arnoud J. Templeton

12.0k total citations · 4 hit papers
152 papers, 8.6k citations indexed

About

Arnoud J. Templeton is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Arnoud J. Templeton has authored 152 papers receiving a total of 8.6k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Oncology, 69 papers in Pulmonary and Respiratory Medicine and 44 papers in Cancer Research. Recurrent topics in Arnoud J. Templeton's work include Prostate Cancer Treatment and Research (42 papers), Inflammatory Biomarkers in Disease Prognosis (28 papers) and Radiopharmaceutical Chemistry and Applications (18 papers). Arnoud J. Templeton is often cited by papers focused on Prostate Cancer Treatment and Research (42 papers), Inflammatory Biomarkers in Disease Prognosis (28 papers) and Radiopharmaceutical Chemistry and Applications (18 papers). Arnoud J. Templeton collaborates with scholars based in Switzerland, Canada and Spain. Arnoud J. Templeton's co-authors include Eitan Amir, Alberto Ocaña, Francisco Vera-Badillo, Ian F. Tannock, Boštjan Šeruga, Mairéad G. McNamara, Jennifer J. Knox, Raya Leibowitz‐Amit, Guru Sonpavde and Priya Aneja and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Arnoud J. Templeton

143 papers receiving 8.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis

2014 2.3k citations Arnoud J. Templeton, Mairéad G. McNamara et al. JNCI Journal of the National Cancer Institute profile →
Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab

2017 690 citations Sabine Schmid, Arnoud J. Templeton et al. profile →
Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis

2014 546 citations Arnoud J. Templeton, Olga Ace et al. Cancer Epidemiology Biomarkers & Prevention profile →
Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis

2017 478 citations Danielle Desautels, Arnoud J. Templeton et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Arnoud J. Templeton Switzerland	40	5.6k	2.6k	1.9k	1.5k	1.2k	152	8.6k
Boštjan Šeruga Canada	34	4.4k 0.8×	1.8k 0.7×	1.6k 0.9×	809 0.5×	736 0.6×	124	7.4k
Howard Gurney Australia	44	5.9k 1.0×	3.4k 1.3×	1.4k 0.7×	2.9k 1.9×	844 0.7×	286	9.5k
Marina Talamonti United States	46	4.8k 0.8×	2.0k 0.8×	1.5k 0.8×	2.6k 1.7×	1.6k 1.4×	208	8.3k
Patricia Keegan United States	54	5.0k 0.9×	3.1k 1.2×	1.6k 0.9×	726 0.5×	1.3k 1.1×	140	9.3k
Gilberto de Castro Brazil	36	8.0k 1.4×	5.4k 2.0×	1.8k 0.9×	943 0.6×	1.3k 1.1×	215	10.7k
Esther Bastiaannet Netherlands	45	4.5k 0.8×	1.6k 0.6×	1.8k 0.9×	1.6k 1.0×	434 0.4×	263	6.9k
Francisco Vera-Badillo Canada	27	3.4k 0.6×	1.6k 0.6×	1.2k 0.7×	902 0.6×	656 0.6×	76	5.5k
Sylvie Rottey Belgium	39	4.1k 0.7×	3.1k 1.2×	949 0.5×	1.6k 1.1×	1.0k 0.9×	236	7.9k
Sinéad Cuffe Ireland	27	8.6k 1.5×	5.8k 2.2×	1.7k 0.9×	875 0.6×	1.9k 1.6×	102	11.1k
Rossana Berardi Italy	45	4.2k 0.7×	2.8k 1.1×	1.4k 0.7×	1.1k 0.8×	541 0.5×	344	7.4k

Countries citing papers authored by Arnoud J. Templeton

Since Specialization

Citations

This map shows the geographic impact of Arnoud J. Templeton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arnoud J. Templeton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arnoud J. Templeton more than expected).

Fields of papers citing papers by Arnoud J. Templeton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arnoud J. Templeton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arnoud J. Templeton. The network helps show where Arnoud J. Templeton may publish in the future.

Co-authorship network of co-authors of Arnoud J. Templeton

This figure shows the co-authorship network connecting the top 25 collaborators of Arnoud J. Templeton. A scholar is included among the top collaborators of Arnoud J. Templeton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arnoud J. Templeton. Arnoud J. Templeton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Engelbrecht, Swantje, et al.. (2025). ER+ HER2− Invasive Breast Cancer: Tumor Remission following Viscum Album Extract/Influenza Vaccine Treatment – A Report of 2 Cases. Complementary Medicine Research. 32(2). 176–181. 1 indexed citations

Fankhauser, Christian D., Marian S. Wettstein, Ailsa J. Christiansen, et al.. (2024). Cut-offs for relapse detection in men with stage I testicular germ cell tumors during active surveillance within a prospective multicentre cohort study using either raw or housekeeper normalized miR-371a-3p serum levels. Urologic Oncology Seminars and Original Investigations. 42(12). 455.e9–455.e13.

Kudura, Ken, et al.. (2023). Predictive Value of Total Metabolic Tumor Burden Prior to Treatment in NSCLC Patients Treated with Immune Checkpoint Inhibition. Journal of Clinical Medicine. 12(11). 3725–3725. 4 indexed citations

Pandiella, Atanasio, Emiliano Calvo, Víctor Moreno, et al.. (2023). Considerations for the clinical development of immuno-oncology agents in cancer. Frontiers in Immunology. 14. 1229575–1229575. 2 indexed citations

Calgua, Byron, Clémentine Le Magnen, Salvatore Piscuoglio, et al.. (2023). Cell-Free DNA Genomic Profiling and Its Clinical Implementation in Advanced Prostate Cancer. Cancers. 16(1). 45–45. 1 indexed citations

Tibau, Ariadna, et al.. (2022). Clinical benefit of cancer drugs approved in Switzerland 2010–2019. PLoS ONE. 17(6). e0268545–e0268545. 3 indexed citations

Saleh, Ramy, Nicholas Meti, Domen Ribnikar, et al.. (2020). Associations between safety, tolerability, and toxicity and the reporting of health‐related quality of life in phase III randomized trials in common solid tumors. Cancer Medicine. 9(21). 7888–7895. 4 indexed citations

Templeton, Arnoud J., Eitan Amir, & Ian F. Tannock. (2020). Informative censoring — a neglected cause of bias in oncology trials. Nature Reviews Clinical Oncology. 17(6). 327–328. 49 indexed citations

Ribnikar, Domen, Igor Stukalin, Philippe L. Bédard, et al.. (2020). The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer. Current Oncology. 28(1). 107–114. 9 indexed citations

10.

Moos, Roger von, Hanne Hawle, Stefanie Hayoz, et al.. (2018). Incidence of hypocalcemia in a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w): SAKK 96/12 (REDUSE). Annals of Oncology. 29. viii609–viii610. 4 indexed citations

11.

Klein, Sabine D., et al.. (2017). Erfahrungen am Lebensende: Eine Umfrage bei Ärzten und Pflegenden eines Spitals für anthroposophisch erweiterte Medizin. Complementary Medicine Research. 25(1). 38–43. 5 indexed citations

12.

Ethier, Josée-Lyne, Danielle Desautels, Arnoud J. Templeton, et al.. (2017). Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis. Gynecologic Oncology. 145(3). 584–594. 88 indexed citations

13.

Khoja, Leila, Eshetu G. Atenafu, Arnoud J. Templeton, et al.. (2016). The full blood count as a biomarker of outcome and toxicity in ipilimumab‐treated cutaneous metastatic melanoma. Cancer Medicine. 5(10). 2792–2799. 65 indexed citations

14.

Vera-Badillo, Francisco, Monika K. Krzyzanowska, Shabbir M.H. Alibhai, et al.. (2016). Honorary and ghost authorship in reports of randomised clinical trials in oncology. European Journal of Cancer. 66. 1–8. 18 indexed citations

15.

Vera-Badillo, Francisco, Martin C. Chang, Alberto Ocaña, et al.. (2015). Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer. Journal of Clinical Pathology. 68(10). 839–843. 6 indexed citations

16.

Ocaña, Alberto, Dolores C. Garcı́a-Olmo, Arnoud J. Templeton, et al.. (2015). Circulating DNA and Survival in Solid Tumors. Cancer Epidemiology Biomarkers & Prevention. 25(2). 399–406. 31 indexed citations

17.

Templeton, Arnoud J., Olga Ace, Mairéad G. McNamara, et al.. (2014). Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. Cancer Epidemiology Biomarkers & Prevention. 23(7). 1204–1212. 546 indexed citations breakdown →

18.

Soest, Robert J. van, Arnoud J. Templeton, Francisco Vera-Badillo, et al.. (2014). Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Annals of Oncology. 26(4). 743–749. 112 indexed citations

19.

Rocha, Pedro, Charity J. Morgan, Arnoud J. Templeton, et al.. (2014). Prognostic Impact of C-Reactive Protein in Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis. Oncology Research and Treatment. 37(12). 772–776. 15 indexed citations

20.

Gillessen, Silke, Arnoud J. Templeton, Giancarlo Marra, et al.. (2010). Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer. JNCI Journal of the National Cancer Institute. 102(23). 1760–1770. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact